Literature DB >> 25701232

Cationic antimicrobial peptide resistance mechanisms of streptococcal pathogens.

Christopher N LaRock1, Victor Nizet2.   

Abstract

Cationic antimicrobial peptides (CAMPs) are critical front line contributors to host defense against invasive bacterial infection. These immune factors have direct killing activity toward microbes, but many pathogens are able to resist their effects. Group A Streptococcus, group B Streptococcus and Streptococcus pneumoniae are among the most common pathogens of humans and display a variety of phenotypic adaptations to resist CAMPs. Common themes of CAMP resistance mechanisms among the pathogenic streptococci are repulsion, sequestration, export, and destruction. Each pathogen has a different array of CAMP-resistant mechanisms, with invasive disease potential reflecting the utilization of several mechanisms that may act in synergy. Here we discuss recent progress in identifying the sources of CAMP resistance in the medically important Streptococcus genus. Further study of these mechanisms can contribute to our understanding of streptococcal pathogenesis, and may provide new therapeutic targets for therapy and disease prevention. This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antimicrobial peptide; Cathelicidin; Defensin; LL-37; Streptococcus virulence factors, innate immunity

Mesh:

Substances:

Year:  2015        PMID: 25701232      PMCID: PMC4539303          DOI: 10.1016/j.bbamem.2015.02.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  97 in total

1.  Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family.

Authors:  W M Shafer; X Qu; A J Waring; R I Lehrer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

2.  A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection.

Authors:  Cheryl Y M Okumura; Andrew Hollands; Dan N Tran; Joshua Olson; Samira Dahesh; Maren von Köckritz-Blickwede; Wdee Thienphrapa; Courtney Corle; Seung Nam Jeung; Anna Kotsakis; Robert A Shalwitz; Randall S Johnson; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2012-02-28       Impact factor: 4.599

3.  The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design.

Authors:  Nina M van Sorge; Jason N Cole; Kirsten Kuipers; Anna Henningham; Ramy K Aziz; Ana Kasirer-Friede; Leo Lin; Evelien T M Berends; Mark R Davies; Gordon Dougan; Fan Zhang; Samira Dahesh; Laura Shaw; Jennifer Gin; Madeleine Cunningham; Joseph A Merriman; Julia Hütter; Bernd Lepenies; Suzan H M Rooijakkers; Richard Malley; Mark J Walker; Sanford J Shattil; Patrick M Schlievert; Biswa Choudhury; Victor Nizet
Journal:  Cell Host Microbe       Date:  2014-06-11       Impact factor: 21.023

4.  Recognition of antimicrobial peptides by a bacterial sensor kinase.

Authors:  Martin W Bader; Sarah Sanowar; Margaret E Daley; Anna R Schneider; Uhnsoo Cho; Wenqing Xu; Rachel E Klevit; Hervé Le Moual; Samuel I Miller
Journal:  Cell       Date:  2005-08-12       Impact factor: 41.582

5.  Penicillin-binding protein 1a promotes resistance of group B streptococcus to antimicrobial peptides.

Authors:  Andrea Hamilton; David L Popham; David J Carl; Xavier Lauth; Victor Nizet; Amanda L Jones
Journal:  Infect Immun       Date:  2006-11       Impact factor: 3.441

6.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis.

Authors:  Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

Review 7.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

8.  M protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A Streptococcus.

Authors:  Jason N Cole; Morgan A Pence; Maren von Köckritz-Blickwede; Andrew Hollands; Richard L Gallo; Mark J Walker; Victor Nizet
Journal:  MBio       Date:  2010-08-31       Impact factor: 7.867

9.  The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion.

Authors:  Christoph M Ernst; Petra Staubitz; Nagendra N Mishra; Soo-Jin Yang; Gabriele Hornig; Hubert Kalbacher; Arnold S Bayer; Dirk Kraus; Andreas Peschel
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

10.  Variation in Streptococcus pneumoniae susceptibility to human antimicrobial peptides may mediate intraspecific competition.

Authors:  Michelle G J L Habets; Daniel E Rozen; Michael A Brockhurst
Journal:  Proc Biol Sci       Date:  2012-07-04       Impact factor: 5.349

View more
  35 in total

1.  Group A Streptococcus Infection of the Nasopharynx Requires Proinflammatory Signaling through the Interleukin-1 Receptor.

Authors:  Doris L LaRock; Raedeen Russell; Anders F Johnson; Shyra Wilde; Christopher N LaRock
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

2.  Quinazoline-Based Antivirulence Compounds Selectively Target Salmonella PhoP/PhoQ Signal Transduction System.

Authors:  María Ayelén Carabajal; Christopher R M Asquith; Tuomo Laitinen; Graham J Tizzard; Lucía Yim; Analía Rial; José A Chabalgoity; William J Zuercher; Eleonora García Véscovi
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 3.  Two-Component Signal Transduction Systems in the Human Pathogen Streptococcus agalactiae.

Authors:  Lamar Thomas; Laura Cook
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

Review 4.  Bacterial strategies of resistance to antimicrobial peptides.

Authors:  Hwang-Soo Joo; Chih-Iung Fu; Michael Otto
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-05-26       Impact factor: 6.237

5.  Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?

Authors:  Maria S Zharkova; Dmitriy S Orlov; Olga Yu Golubeva; Oleg B Chakchir; Igor E Eliseev; Tatyana M Grinchuk; Olga V Shamova
Journal:  Front Cell Infect Microbiol       Date:  2019-04-30       Impact factor: 5.293

6.  Genomic Landscape of Intrahost Variation in Group A Streptococcus: Repeated and Abundant Mutational Inactivation of the fabT Gene Encoding a Regulator of Fatty Acid Synthesis.

Authors:  Jesus M Eraso; Randall J Olsen; Stephen B Beres; Priyanka Kachroo; Adeline R Porter; Waleed Nasser; Paul E Bernard; Frank R DeLeo; James M Musser
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

7.  Group A Streptococcal M1 Protein Sequesters Cathelicidin to Evade Innate Immune Killing.

Authors:  Christopher N LaRock; Simon Döhrmann; Jordan Todd; Ross Corriden; Joshua Olson; Timo Johannssen; Bernd Lepenies; Richard L Gallo; Partho Ghosh; Victor Nizet
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

Review 8.  Variation, Indispensability, and Masking in the M protein.

Authors:  Partho Ghosh
Journal:  Trends Microbiol       Date:  2017-08-31       Impact factor: 17.079

Review 9.  Beyond conventional antibiotics - New directions for combination products to combat biofilm.

Authors:  Danir Fanisovich Bayramov; Jennifer Ann Neff
Journal:  Adv Drug Deliv Rev       Date:  2016-08-03       Impact factor: 15.470

Review 10.  Enzymes required for the biosynthesis of N-formylated sugars.

Authors:  Hazel M Holden; James B Thoden; Michel Gilbert
Journal:  Curr Opin Struct Biol       Date:  2016-05-20       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.